Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | SVP, Business Development | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 494,197 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Sale · Disposed 42,431 · Balance 494,197 F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 18:51 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 42,431 | $8.27 | $350,730.40 |
DisclosureSEC source: 0001702031-26-000002 · ownership.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 494,197 F1 · shares: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 17:51 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-059784 · ownership.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,628 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 16:46 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Tax withholdingCommon Stock | 26,941 | $4.76 | $128,239.16 |
DisclosureSEC source: 0000950170-25-032281 · ownership.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,628 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 19:44 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024486 · ownership.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,569 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 16:46 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 8,684 | $4.13 | $35,884.02 |
DisclosureSEC source: 0000950170-24-027249 · ownership.xml · nonDerivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,569 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.1306 to $4.1339, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:46 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 8,727 | $4.30 | $37,494.68 |
DisclosureSEC source: 0000950170-24-027249 · ownership.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,253 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.28 to $4.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 16:50 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-018024 · ownership.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,980 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 18:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 8,268 | $6.26 | $51,790.75 |
DisclosureSEC source: 0001209191-23-016460 · doc4.xml · nonDerivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,980 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2301 to $6.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 18:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 8,509 | $6.20 | $52,793.24 |
DisclosureSEC source: 0001209191-23-016460 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,248 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.1901 to $6.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:08 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001209191-23-011338 · doc4.xml · derivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2033-02-15 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 16, 2024, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:08 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 32,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011338 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,757 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2024, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 17:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001209191-22-047887 · doc4.xml · derivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2022-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested in 48 equal monthly installments beginning on December 7, 2012. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 17:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 1,250 | $3.12 | $3,900.00 |
DisclosureSEC source: 0001209191-22-047887 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2022 Filed Mar 2, 2022 21:26 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 11,517 | $11.27 | $129,791.98 |
DisclosureSEC source: 0001209191-22-015154 · doc4.xml · nonDerivative · entry 3 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,807 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.20 to $11.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:26 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 4,084 | $11.19 | $45,699.96 |
DisclosureSEC source: 0001209191-22-015154 · doc4.xml · nonDerivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,324 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $11.36 | $0.00 |
DisclosureSEC source: 0001209191-22-015154 · doc4.xml · derivative · entry 4 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2032-02-27 F4 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 28, 2023, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 32,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015154 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,408 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2023, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 18:39 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 16,620 | $18.19 | $302,272.93 |
DisclosureSEC source: 0001209191-21-017272 · doc4.xml · nonDerivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,708 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:39 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,845 | $18.66 | $71,743.86 |
DisclosureSEC source: 0001209191-21-017272 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,328 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.53 to $18.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 17:15 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $20.28 | $0.00 |
DisclosureSEC source: 0001209191-21-014869 · doc4.xml · derivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2031-02-23 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 17:15 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 32,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-014869 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,173 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 17:00 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 5,535 | $10.66 | $58,984.28 |
DisclosureSEC source: 0001209191-20-016197 · doc4.xml · nonDerivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,473 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $10.8644, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:00 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 12,223 | $10.04 | $122,685.92 |
DisclosureSEC source: 0001209191-20-016197 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,008 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 18:01 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-20-014124 · doc4.xml · derivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-25 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 18:01 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-014124 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,231 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2021, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:25 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 4,020 | $15.93 | $64,021.31 |
DisclosureSEC source: 0001209191-20-002027 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,231 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to a written election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.80 to $16.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 17:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 8,788 | $19.89 | $174,766.96 |
DisclosureSEC source: 0001209191-19-015731 · doc4.xml · nonDerivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,251 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.78 to $20.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 17:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,741 | $20.14 | $75,325.04 |
DisclosureSEC source: 0001209191-19-015731 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,039 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06 to $20.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:18 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $20.62 | $0.00 |
DisclosureSEC source: 0001209191-19-014962 · doc4.xml · derivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-26 F2 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments from the date of grant, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:18 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-014962 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,780 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2020, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 16:34 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 1,619 | $26.09 | $42,231.62 |
DisclosureSEC source: 0001209191-19-001994 · doc4.xml · nonDerivative · entry 3 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,780 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:34 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 1,170 | $26.95 | $31,527.99 |
DisclosureSEC source: 0001209191-19-001994 · doc4.xml · nonDerivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,399 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.87 to $27.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:34 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,272 | $26.30 | $86,050.33 |
DisclosureSEC source: 0001209191-19-001994 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,569 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.87 to $26.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 17:32 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 8,525 | $18.72 | $159,605.05 |
DisclosureSEC source: 0001209191-18-015872 · doc4.xml · nonDerivative · entry 2 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,841 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. The Reporting The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.35 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:32 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $18.85 | $0.00 |
DisclosureSEC source: 0001209191-18-015872 · doc4.xml · derivative · entry 3 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-02-27 F4 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments beginning on February 28, 2018, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:32 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-015872 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,366 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments beginning February 28, 2019, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:09 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 8,568 | $15.26 | $130,776.81 |
DisclosureSEC source: 0001209191-18-002050 · doc4.xml · nonDerivative · entry 1 Birznieks Gunther · CIK 0001702031 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,366 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.25 to $15.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.